CAR-T Clinical Trials

3 recruiting

CAR-T Trials at a Glance

23 actively recruiting trials for car-t are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Durham, Guangzhou, and Hangzhou. Lead sponsors running car-t studies include Second Affiliated Hospital of Guangzhou Medical University, IRCCS Azienda Ospedaliero-Universitaria di Bologna, and The Children's Hospital of Zhejiang University School of Medicine.

Browse car-t trials by phase

Treatments under study

About CAR-T Clinical Trials

Looking for clinical trials for CAR-T? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CAR-T trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CAR-T clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Not Applicable

Nutrition OUtReach In Systems of Healthcare

CAR-T Cell TherapyALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONFood Insecurity+1 more
University of Kansas Medical Center210 enrolled4 locationsNCT06802406
Recruiting
Not Applicable

Coping Skills Training for Symptom Management and Daily Steps (Step Up)

Hematopoietic Stem Cell TransplantCAR-T Cell Therapy
Duke University177 enrolled1 locationNCT06575712
Recruiting
Phase 1Phase 2

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

Leukemia RelapseLymphoma Diffuse Large B-cellLeukemia and Lymphoma+1 more
AvenCell Therapeutics, Inc.178 enrolled13 locationsNCT07284433
Recruiting
Not Applicable

A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

Diffuse Large B Cell LymphomaRadiotherapyCAR-T+1 more
Peking Union Medical College Hospital20 enrolled1 locationNCT05514327
Recruiting

Long-term Follow-up of Subjects Treated With CAR T Cells

AdultCAR-TLong Term Adverse Effects+1 more
Marcela V. Maus, M.D.,Ph.D.45 enrolled1 locationNCT05024175
Recruiting

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Hematopathology Eligible or CAR-t Cell Treatment
The Lymphoma Academic Research Organisation5,000 enrolled36 locationsNCT04328298
Recruiting
Early Phase 1

TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

Small Cell Lung Cancer ( SCLC )CAR-T Cell Therapy
TCRCure Biopharma Ltd.24 enrolled1 locationNCT07246304
Recruiting
Phase 3

CAR-T Long Term Follow Up (LTFU) Study

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals1,400 enrolled118 locationsNCT02445222
Recruiting

Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy

Lymphoma Receiving CAR-T Therapy
Memorial Sloan Kettering Cancer Center120 enrolled1 locationNCT04107285
Recruiting
Phase 1

A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

CAR-T Cell TherapyAcute Myeloid Leukemia (AML)
First Affiliated Hospital of Zhejiang University20 enrolled1 locationNCT07198867
Recruiting
Phase 1

Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS

CAR-T Cell TherapyMulti-Drug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of Medicine18 enrolled1 locationNCT06553898
Recruiting
Not Applicable

Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL

CAR-T Cell TherapyCLLSLL
The Affiliated Hospital of Xuzhou Medical University50 enrolled1 locationNCT07120633
Recruiting
Phase 2

Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy

Prolonged Cytopenia Following CAR-T Therapy
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07127289
Recruiting
Phase 1

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS

CAR-T Cell TherapyMulti-Drug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of Medicine18 enrolled1 locationNCT06842589
Recruiting

Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapies

CAR-T Cell TherapyExtracellular Vesicles
IRCCS Azienda Ospedaliero-Universitaria di Bologna100 enrolled1 locationNCT06554951
Recruiting

Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01)

CAR-T Therapy Complications
IRCCS Azienda Ospedaliero-Universitaria di Bologna150 enrolled1 locationNCT04892433
Recruiting
Early Phase 1

EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)CAR-T
Zhimin Zhai9 enrolled1 locationNCT06642025
Recruiting
Phase 1

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers

Lung CancerCancerImmunotherapy+1 more
Second Affiliated Hospital of Guangzhou Medical University30 enrolled2 locationsNCT03198052
Recruiting
Phase 1

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

Pancreas CancerSolid Tumor, AdultCAR-T Cell Therapy+1 more
Second Affiliated Hospital of Guangzhou Medical University30 enrolled1 locationNCT05779917
Recruiting
Phase 1

GPC3/Mesothelin-CAR-γδT Cells Against Cancers

Liver CancerLung CancerPancreas Cancer+3 more
Second Affiliated Hospital of Guangzhou Medical University30 enrolled1 locationNCT06196294